Epstein-Barr Virus Vaccine Research
The National Institute of Allergy and Infectious Diseases (NIAID) is conducting a research study aimed at stopping the spread of the Epstein-Barr virus (EBV), the main cause of mono. Join our compensated study and further EBV vaccine research today!
Compensation Provided
Conducted in Bethesda, MD
18 - 29
Years Old
Years Old
Fast Facts
About Our Research Study
Help researchers at the NIAID evaluate the safety and immune system response of a new Epstein-Barr virus vaccine. This research could help reduce future cases of mono. Epstein-Barr virus (EBV) infects more than 90% of the world’s population, and when adolescents and young adults contract the virus they are at risk of experiencing serious health complications like developing mono or certain cancers. Currently, there is no vaccine that prevents or treats EBV infection. Join researchers and help stop the spread of EBV! Participation in this research study may inform future treatments. Compensation provided up to $2220. |
Additional Information
Why is this study being done?
The purpose of this research study is to determine the safety and immunogenicity of an EBV vaccine. Participation in this research study may inform future treatments used to prevent EBV, mono, and certain EBV-related cancers.
Is this study for me?
You may qualify for this study if you meet the following criteria.
Eligibility Criteria:
Eligibility Criteria:
- 18 - 29 years old
- In general good health (no major medical conditions)
- No ongoing use of immunosuppressive medications
- No substance use disorder
What will happen if I participate in the study?
Once enrolled, this study involves:
- In-person and virtual visits
- 3 doses of experimental EBV vaccine
- Participant safety evaluation and monitoring
Will I be paid for being in this research study?
Compensation up to $2220 is provided for your time.
Will it cost me anything to participate in this study?
There is no cost for you to participate in our research study.